Advancing combination therapy for Alzheimer's disease Journal Articles

abstract

• AbstractThe study of Alzheimer's disease (AD) has led to an increased understanding of the multiple pathologies and pathways of the disease. As such, it has been proposed that AD and its various stages might be most effectively treated with a combination approach rather than a single therapy; however, combination approaches present many challenges that include limitations of non‐clinical models, complexity of clinical trial design, and unclear regulatory requirements. The Alzheimer's Association Research Roundtable meeting on May 7–8, 2018, discussed the approaches and challenges of combination therapy for AD. Experts in the field (academia, industry, and government) provided perspectives that may help establish a path forward for the development of new combination therapies.

authors

• Salloway, Stephen P
• Sevingy, Jeff
• Budur, Kumar
• Pederson, Jan Torleif
• DeMattos, Ronald B
• Von Rosenstiel, Philipp
• Paez, Hector Antonio
• Evans, Rebecca
• Weber, Christopher J
• Hendrix, James A
• Worley, Susan
• Bain, Lisa J
• Carrillo, Maria C

status

• published 

publication date

• January 2020

published in

• Alzheimer's and Dementia: Translational Research and Clinical Interventions  Journal

keywords

• Alzheimer's disease
• biomarkers
• clinical trials
• combination therapy
• research roundtable

Digital Object Identifier (DOI)

• 10.1002/trc2.12073

start page

• e12073

volume

• 6

issue

• 1